Sermorelin: Research Overview

Sermorelin (also known as GRF 1-29 or sermorelin acetate) is a synthetic 29-amino acid peptide representing the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone (GHRH). It binds and activates the GHRH receptor (GHRHR) on pituitary somatotrophs, stimulating the pulsatile release of endogenous growth hormone (GH). Sermorelin was FDA-approved in 1997 (trade name Geref) for the diagnosis and treatment of pediatric growth hormone deficiency and for diagnostic GH assessment in adults. Commercial production was voluntarily discontinued by the manufacturer in 2008 for commercial — not safety — reasons.

What Is Sermorelin?

Endogenous GHRH is a 44-amino acid hypothalamic peptide that governs pulsatile GH secretion from the pituitary. Sermorelin retains the first 29 residues, which are sufficient for full receptor binding and GH-secretory activity. Its molecular weight is approximately 3,358 Da. Unlike recombinant human growth hormone (rhGH), sermorelin stimulates endogenous GH release rather than supplying exogenous GH directly, preserving physiological GH pulsatility and negative-feedback regulation.

Mechanism of Action

Sermorelin binds GHRHR on pituitary somatotrophs, coupling to Gs protein and stimulating cAMP production. This activates protein kinase A, promotes GH gene transcription, and triggers GH exocytosis. The effect is glucose-independent and does not directly raise IGF-1 except through the downstream action of GH on the liver. Because sermorelin does not bypass the pituitary, the natural negative-feedback axis (somatostatin, IGF-1) remains intact — a theoretical safety advantage over direct rhGH administration.

What the Research Shows

The clinical evidence supporting sermorelin’s original FDA approval was based on its ability to increase GH secretion in GH-deficient children and to normalize growth velocity in multi-year pediatric studies. Walker (Clin Interv Aging, 2006; PMID 18046908) reviewed the rationale for sermorelin in adult-onset GH insufficiency, arguing that stimulating endogenous GH release via GHRH analogues may better preserve GH axis physiology than rhGH replacement.

Large placebo-controlled clinical trials with sermorelin in adults with GH insufficiency — equivalent in scale to the SCALE or SURMOUNT programs for GLP-1 agonists — have not been published. The primary evidence base for adult use consists of smaller studies, reviews, and clinical observations. Sermorelin’s status as a formerly approved compound (and its continued compounded availability) means it occupies a clinical gray zone distinct from purely investigational research peptides.

Reported Dose Ranges

DISCLAIMER: The following information is provided for research reference only and is not medical advice or a recommendation to use this compound. Sermorelin is a prescription compound in the United States and most regulated markets. Its clinical use requires a physician prescription; compounded sermorelin is not FDA-approved.

The original Geref prescribing information specified a diagnostic dose of 1 mcg/kg intravenously for GH stimulation testing in adults. Pediatric treatment doses were subcutaneous daily administration at approximately 30 mcg/kg in the original approval studies. Literature on adult compounded sermorelin use describes doses ranging from approximately 200 to 300 mcg subcutaneously, administered at night to coincide with physiological GH pulsatility, though formal peer-reviewed dose-finding studies in adults at these doses are limited.

Storage

Lyophilized sermorelin should be stored at −20 °C. Reconstituted solutions should be maintained at 2–8 °C and used within 28 days. Sermorelin has a very short plasma half-life of approximately 11–12 minutes and is subject to rapid enzymatic degradation; solutions should not be left at room temperature for extended periods.